Combinations of AKT inhibitor compounds and erlotinib, and methods of use
US9610289B2 · kind B2 · utility
2Cited by
46References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 26, 2015 |
| Grant date | Apr 4, 2017 |
| Priority date | — |
| Expiry date | Aug 26, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/505
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides A combination of, a) a compound of Formula Ia:or a pharmaceutically acceptable salt thereof; and b) erlotinib or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a hyperproliferative disorder, such as cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.